Our findings are anticipated to contribute to the development of more effective and safer clinical treatment options for HER2-positive breast cancer with liver metastasis, while simultaneously providing valuable data to enhance our understanding of the heterogeneity associated with breast cancer liver metastasis. The gene discussed is ERBB2; the disease is breast carcinoma.